Blood clotting is a complex, multifactorial physiological process that allows the body to respond to thrombogenic stimuli (e.g. a blood vessel being damaged). If the body’s physiological response is excessive, a pathologic thrombosis with vessel occlusion and tissue ischaemia may occur leading to myocardial infarctions, strokes, pulmonary embolisms, etc. When a person’s physiological response is insufficient, it may result in excessive bleeding.



Thrombotic disorders and cardiovascular diseases such as thrombosis, myocardial infarctions, strokes, embolisms, etc. are the main cause of death and disability in Europe.
In Italy, cardiovascular diseases cause 35% of male deaths and 43% of female deaths. They have a huge impact on public health and weigh heavily on health and economic resources.
Spending on cardiovascular surgery is estimated at approximately €650 million. Over €5 billion is spent on medication for these disorders.

Source of data: ISTAT


Smart Clot

  • This is an innovative and unique in vitro device that provides, just in few minutes, a semi quantitative dynamic analysis of platelets aggregation and fibrin formation with far greater accuracy than presently possible on the market.
  • Measuring platelet activation and fibrin formation using a blood sample helps clinicians to chart the thrombogenic potential of a sample and work out a patient’s predisposition to forming thrombi.
  • The Smart Clot platform helps specialists (anaesthetists, haematologists, cardiologists, heart surgeons, etc.) to both accurately evaluate blood clotting disorders and monitor the effect of antiplatelet and/or anticoagulation therapy.